info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Osteoarthritis Companies

Osteoarthritis (OA) companies specialize in the development and delivery of products and solutions related to the diagnosis, treatment, and management of osteoarthritis—a degenerative joint disease characterized by the breakdown of cartilage. These companies contribute to addressing the needs of individuals affected by OA, which is a prevalent and chronic condition.

Osteoarthritis CompaniesLatest Osteoarthritis Companies Update



  • November 2023: For the treatment of pain and inflammation associated with soft tissue surgery and chronic osteoarthritis (OA) in canines, Krka introduced Robexera, the first generic robenacoxib solution. Anti-inflammatory pain relief is provided by the once-daily administration regimen of Robexera, a COX2-NSAID formulation. To assist pet caretakers in administration, the product is presented as a flavored chewable tablet. A set of perforated blisters, four strengths of PIL sheets that convert to prescribing envelopes, and color-coded cases are included in each pack to facilitate dispensing. With its bioequivalence to the originator product, Robexera offers veterinary practices and their clients improved affordability and targeted pain relief. This is especially beneficial for clients whose animals are undergoing long-term pain management programs or have other health conditions, as it further enhances the value proposition for these practices.




  • July 2023: Swiss pharmaceutical company Sandoz announced the launch of a biosimilar version of the drug. Aside from offering an unbranded version of Humira at an 81% discount, the Novartis-owned company stated that its medication, Hyrimoz, would be priced at a 5% reduction from Humira's current published price of $6,922 per month. As a means of attracting pharmacy benefit managers, which base a portion of their revenue on the discounts they negotiate on behalf of their clients—large employers and health insurance plans—drug manufacturers will likely introduce Humira biosimilars with modest discounts, according to healthcare experts. As opposed to pharmacy benefit managers, which typically do not pursue after-market discounts, healthcare systems that function as both providers and insurers may be drawn to the more affordable variant.


List of Osteoarthritis Key companies in the market

  • Abbott

  • Novartis AG

  • Pfizer Inc.

  • Eli Lilly and Company.

  • ABIOGEN PHARMA S.p.A

  • Merck Sharp & Dohme Corp.

  • TissueGene Inc.

  • Ampio Pharmaceuticals Inc.

  • Regeneron

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.